Skip to main content

While congressional debate over the repeal and replacement of the Affordable Care Act managed to draw much of the attention away from the biotech sector Friday morning, a few companies caught investors' eyes, including Immunomedics (IMMU)

The cancer drug research company hit new highs on Thursday, closing at $6.63 per share, up 3.2% from market's open. The company continued its upward trend Friday ahead of the opening bell. Shares were up 4.8% ahead of market's open, hitting $6.95 apiece. 

Meanwhile, PTC Therapeutics (PTC) , a microcap biotech with Duchenne Muscular Dystrophy drugs, was falling quickly ahead of market's open. Shares were down 4.8%, hitting $8.04 apiece after performing poorly on Thursday. Shares fell 2.2% during normal trading hours Thursday. Last week PTC paid $140 million in cash to acquire Marathon Pharmaceuticals' Emflaza, a DMD drug mired in a price-gouging controversy.

Mylan (MYL) shares were also falling Friday ahead of the opening bell. The EpiPen-maker saw shares fall 2.9% ahead of market's open, hitting $40.41 apiece. This was likely thanks to reports that the company is recalling 81,000 EpiPens in  Australia, New Zealand, Europe and Japan this past week. 

Finally, Rigel Pharmaceuticals (RIGL) were trading at heaving volume ahead of market's open. Shares were up 1.6%, hitting $3.10 apiece after the company climbed 10% Thursday.